Human in the Loop, Always: How Prof. M. M. Ananth Framed the Future of AI in Indian Healthcare

PANEL REPORT · ACSF INDIA · 15 NOVEMBER 2026

Human in the Loop, Always: How Prof. M. M. Ananth Framed the Future of AI in Indian Healthcare

At an online panel hosted by the Association of Commonwealth Scholars and Fellows (ACSF) India, the Founder of AcadNet brought hard numbers, a four-part model for collaboration and a concrete proposal to one question: can AI make quality healthcare affordable and accessible where it is needed most?

By AcadNews Editorial · AN

Sunday mornings are a hard sell for any online event. This one filled up anyway. On 15 November 2026, ACSF India put five senior voices from medicine, technology, policy and health economics on one Zoom screen and asked them a blunt question about artificial intelligence in healthcare: who does it actually reach?

One of those voices was Prof. (Dr.) M. M. Ananth, Founder of AcadNet (Academic Network) and Founding Vice Chancellor of Adani University. A Cambridge-trained materials scientist and a Commonwealth and DAAD (German Academic Exchange Service) Fellow, he brought a wide lens to the table: evidence on how far AI has really travelled, a sober warning about generative AI, and a plan to turn the conversation into something India can use.

15 Nov
Sunday, 2026
11:00
to 12:30 PM IST
Zoom
Online, with registration through ACSF India
ACSF
Association of Commonwealth Scholars and Fellows, India
▼THE PANEL

Five voices, one stubborn question

The session, titled Artificial Intelligence in Healthcare: Making Quality Healthcare Affordable and Accessible in Marginalised Regions, was moderated by Prof. Adarsh Kumar, Director of the UP Forensic Science Laboratory. Prof. (Dr.) Sanjay Kataria, President of ACSF India, opened it by calling healthcare a basic human need, not a privilege, and by saying AI should be an enabling tool for professionals, never a replacement for them. He added that the real measure of success is how many more lives are touched, not how advanced the technology looks.

MODERATOR
Prof. Adarsh Kumar
Prof. Adarsh Kumar
Director, UP Forensic Science Laboratory
Prof. (Dr.) Thipendra P. Singh
Prof. (Dr.) Thipendra P. Singh
Founding Pro Vice Chancellor, Chandigarh University, Uttar Pradesh
Prof. (Dr.) M. M. Ananth
Prof. (Dr.) M. M. Ananth
Founder, AcadNet; Founding Vice Chancellor, Adani University
Dr. Rahul Singh Amritraj
Dr. Rahul Singh Amritraj
CEO and Director, Centre for Medical Innovation, GIMS (Govt. of UP)
Dr. Ravdeep Kaur
Dr. Ravdeep Kaur
Director, Global Health Strategies
▼ROUND ONE: THE BASELINE

Every seat gave its two minutes

Prof. Adarsh Kumar opened by cutting through the hype. AI is not going to cure every disease by next Sunday, he said, and it is not going to replace doctors altogether. The question has moved from what AI can do in the lab to what actually works at the bedside, in a country where high-volume tertiary centres sit beside resource-constrained clinics. The real challenge, he said, is clinical validation, workflow integration, data privacy and medico-legal accountability when an AI tool joins the decision. Each panellist then took two minutes on where AI in healthcare stands today.

Prof. (Dr.) Thipendra P. Singh
FOUNDING PRO VICE CHANCELLOR, CHANDIGARH UNIVERSITY

Prof. Singh went first. AI, he said, has moved out of pilot projects into large-scale clinical deployment, across diagnosis, medical imaging, drug discovery, disease prediction, telemedicine and clinical documentation. In the United States, roughly 1,500 AI-enabled medical devices had been authorised by last December, about three-fourths of them in radiology.

In India, he said, ABDM (Ayushman Bharat Digital Mission) has recorded about 95 crore ABHA (Ayushman Bharat Health Account) IDs, along with some 120 crore linked health records across more than 5 lakh health facilities and 11 lakh professionals. eSanjeevani has crossed 44.9 crore teleconsultations. TB screening and Madhu Netra AI show where AI has already made a path.

Calling himself the least medical person on the panel, he said he could offer the data while practitioners supply the insight. The bigger challenge now, he added, is clinical evidence and clinical validation.

▼PROF. ANANTH OPENS

Read the numbers carefully

Asked for two minutes on the current state of AI in healthcare, Prof. Ananth built on the figures Prof. Singh had just shared and took the longer view. Eleven months earlier, he said, he had hosted an online panel called Healing at Scale: Democratizing Healthcare. There, Dr. Mohan, a Padma Shri awardee and Humboldt Fellow, showed how AI was already working inside his own institution. That left Prof. Ananth convinced that adoption is moving faster than the records suggest.

He then sorted the evidence under headings. On strategy and governance, India looks better than its reputation. Only 4 of the 50 countries in Europe have a health-specific AI strategy, while India launched SAHI (Strategy for Artificial Intelligence in Healthcare for India) and BODH (Benchmarking Open Data Platform for Health AI) in February 2026. The ICMR (Indian Council of Medical Research) has issued its own guidelines too.

2.4%
of devices with clinical studies relied on randomised trial data, he said
4 of 50
countries in Europe have a health-specific AI strategy
Feb 2026
India’s SAHI and BODH frameworks launched, with ICMR guidelines already issued

On clinical impact, he was more cautious. What an AI system delivers depends on what it learned from, so the sanctity and sanity of the data speak volumes. Only 2.4 per cent of devices with clinical studies relied on randomised trial data, and application-oriented research is a small slice of the total, about 3.3 per cent globally. India, he said, is yet to make a mark there.

GLOBAL AI-IN-HEALTH PUBLICATIONS, PUBMED-INDEXED
2024
28,180 papers
2025
49,394 papers

India fares better on volume: in a 2023 bibliometric analysis it ranked second in the world, behind the United States. Generative AI papers are fewer, with 2,761 in one corpus and 383 of them from India. Real impact, in his reading, sits in medical imaging, diagnostics, screening and public health. Clinical documentation, telemedicine and remote monitoring come next, and drug discovery is speeding up with better tools and hardware. India is moving slowly, he added, and rightly so: with a human in the loop, each decision costs a life if it goes wrong.

▼ROUND ONE, CONTINUED

The hospital floor and the health economist

Dr. Rahul Singh Amritraj
CEO AND DIRECTOR, CENTRE FOR MEDICAL INNOVATION, GIMS (GOVT. OF UP)

Dr. Amritraj spoke from the hospital space. His centre has set up an innovation centre in a government hospital and launched what he called the country’s first AI clinic in a government hospital. With all the buzz, he said, a new kind of quackery is entering the ecosystem in the name of AI: unvalidated, unregulated and ethically doubtful.

Medical-grade AI is different. It has to be trained on clinically validated, regulated data, with doctors as co-creators of the model. Clinical decision support, he said, is the one thing healthcare needs from AI. Opinion is not validation. Clinical validation is an institutional process, and too many startups claim it but cannot answer when asked for a CTRI (Clinical Trials Registry of India) number or the sample data.

He also raised data safety while data is at rest, in transit and in execution, and noted that under the DPDP (Digital Personal Data Protection) Act, health data belongs to patients.

Dr. Ravdeep Kaur
DIRECTOR, GLOBAL HEALTH STRATEGIES

Speaking as a health economist, Dr. Kaur said the field is outrunning the evidence and the reimbursement rules built for it. The foundational question, she said, is what data the learning model uses. India still leans on global or Southeast Asian reference data and lacks its own reference cases, and its costing data is limited. Feed that into an AI model, and the output can sit far from the evidence that financing decisions need.

She asked for the marginal return on the money being invested and, after screening, how many people actually get treated. Playing devil’s advocate, she said, the answer has to bring the human perspective back into the loop.

▼SEGMENT ONE: PRACTICAL APPLICATIONS

Taking diagnosis to the patient

The moderator’s first question went to Prof. Singh: which AI tools can bypass high-end diagnostic infrastructure in marginalised regions?

Prof. Singh on tools and conditions
THE ANSWER

Affordable, portable, smartphone-enabled devices, he said, especially in imaging. He named Qure.ai’s qXR, which reads chest X-rays for early TB and lung disease screening without a radiologist, and Madhu Netra AI for diabetic retinopathy. He added AI-enabled ECG devices and digital stethoscopes for preliminary cardiac checks, and Butterfly iQ, a handheld ultrasound with AI guidance for trained frontline workers. AI-assisted decision support through telemedicine can connect health workers with specialists, with IoT (internet of things) and sensing devices in the mix.

Three conditions are essential, he said: affordability, validation on Indian populations, and reliable referral. An AI screen must never be mistaken for a definitive diagnosis. It is assistive, and its job is to cut the geographic, economic and infrastructural barriers, not to replace expensive infrastructure or medical professionals.

Prof. Singh on screening and triage
POPULATION-LEVEL VIEW

Asked how AI can work as a population-level screening and triage tool, he made four points. Screen the population early. Stratify people into critical, moderate and low risk so that consultations and referrals go to those who need them first. Let ASHA (Accredited Social Health Activist) workers and primary health centres screen communities with smartphone-based AI apps and portable devices, so outbreaks can be sensed early. And allocate resources intelligently by linking screening with telemedicine, hospital information systems, beds and referral networks.

His central argument was a shift from a hospital-centric, treatment-oriented model to a population-centric, prevention-oriented one. He also reminded the room that every digital thing is not AI.

▼BEYOND THE CLOUD

The ecosystem matters more than the tool

The moderator asked a practical question: do AI models work reliably offline, or in areas with weak connectivity? Prof. Ananth answered with candour. Moving a large medical image to the cloud is a real limitation in India. But tools with web-based interfaces are emerging, and he pointed to a precision-medicine tool for diabetes, shared by Dr. Mohan, that classifies type 2 diabetes into distinct pathophysiological endotypes and predicts associated complications.

The bigger point, in his view, was not any single tool. Healthcare AI is an ecosystem of infrastructure, policy, devices and medicine, and for the first time policymakers, device makers and doctors are all talking to each other. Earlier, ICMR did its thing, doctors did theirs, and everyone worked in silos. He sees the same shift in the move from Industry 4.0 to Industry 5.0.

▼SEGMENT ONE, CONTINUED

Accountability, validation and repurposing

Then the moderator turned to Dr. Amritraj, who had been sharply critical earlier: would frontline workers treat AI as decision support or as a standalone diagnosis?

Dr. Amritraj on accountability
THE ANSWER

A black-and-white line, he said: a tool is either validated or it is not. A medical licence is given to an individual who stays accountable for the decision, so the doctor decides. The moment a screen is connected to the internet, he said, it becomes software as a medical device and must be regulated. If I am driving the car, he said, I am accountable. He recalled a news report from about three months earlier in which a patient altered a psychiatrist’s prescription through AI, got the medicine and died, and the court then went after the doctor.

The moderator backed this with a familiar example. Reports and OPD (outpatient department) papers often end with a line saying the finding is not for medico-legal purposes, as if that absolves everyone. It does not.

Validation, Dr. Amritraj explained, follows a path: a protocol, a statement of which patients were included and why, the sample size, a principal investigator, the research committee, then the ethics committee approved by CDSCO (Central Drugs Standard Control Organisation), and finally a test licence. Without that, it is only a proof of concept. Medical-grade voice samples, he added, cannot be gathered at a metro station or a university.

He also urged hospitals to help Indian startups grow by giving them doctors, data and a window to test. As an example of technology repurposing, he described a TB screening tool built for community use that his hospital placed in its own X-ray room. Among about 800 X-rays, it picked up patients who had no idea they had TB, an accidental finding. He described AI for an India that works on mobile signals, not only smartphones, and said clinical-grade AI must stay simple and let doctors say what they want said, because accountability is theirs. He noted that the NMC (National Medical Commission) offers a free six-month AI certificate course for doctors, and said hospitals that validate a solution should also buy it.

▼THE FOUR Cs

Confident nonsense, and what to do about it

After Dr. Amritraj spoke sharply about unvalidated AI tools entering Indian hospitals, Prof. Ananth added two sentences that became the most repeated idea of the day. AI itself is old, he said, with roots in the 1956 era. Classic AI predicts. Generative AI creates. And the creative ability is exactly where hallucination comes from.

AI can assert a confident nonsense and human in loop is prominently important.
PROF. M. M. ANANTH

He recalled using AI for new product development at Cambridge some thirty years ago, when hardly anyone used the term. What has changed is the generative capability, which is why final accountability and decision making must stay with a person. The moderator summed it up in a phrase the panel kept returning to: augmentation, not replacement.

His answer to how a sector this fragmented should move was a framework he called the four Cs.

01
Cooperation
All sectors involved, technologists included, agree to work in the same room.
02
Collaboration
Doctors bring the medical view, technologists the implementation view, AI specialists the AI understanding.
03
Co-creation
Solutions are built together, not handed over. Models are trained with clinicians beside the developers.
04
Co-evolution
Systems, people and policy keep adapting to one another. Without it, he said, the effort will not be constructive.
▼SEGMENT TWO: AFFORDABILITY AND ACCESS

Who pays, and what it returns

The moderator asked Dr. Kaur which public-private partnership or startup models can lower the cost of deploying AI in low-resource regions.

Dr. Kaur on access and claims
THE FIRST ANSWER

Affordability and accessibility go hand in hand, she said, and validation by authorities such as WHO and ICMR, plus regulators, is the safety check. What she values in AI is that it stretches scarce specialists through task shifting. ASHA workers using AI eye-screening devices, she said, agreed with ophthalmologists 91 per cent of the time. Handheld X-rays can help screen for TB, which India still has to eliminate. She stressed screening, not diagnosing, and warned that data poverty leaves populations and care settings underrepresented in digital data.

Her example on insurance was PM-JAY (Pradhan Mantri Jan Arogya Yojana), which processes about 50,000 claims a day. Only 15 to 20 per cent are auto-adjudicated, she said, so around 80 per cent of the burden is still manual. Machine learning, language processing, OCR (optical character recognition) and large language models can help, but with a human in the loop. A wrongly rejected claim raises out-of-pocket costs, and payment delays push private hospitals out of the scheme. AI-based pre-submission checks can flag missing documents and mismatched packages. A senior insurer colleague told her that a human sits at the end of every rejection: AI may approve fast, but it does not deny alone. Performance data, she said, should be a publicly auditable scorecard.

Dr. Kaur on pricing
THE FOLLOW-UP

AI will not make healthcare free, she said. It is an added cost, so the test is whether it earns its marginal cost. She suggested flat yearly pricing and volume-based, tender-style bulk purchasing. Start narrow with two or three use cases chosen on volume and evidence, such as TB screening, eye screening and claims processing. Run pilots in shadow mode, where AI works alongside people without deciding anything. Build India’s own reference cases. Pay for treated cases rather than screens, pool purchasing across states to bring prices down, and consider extending PM-JAY from inpatient to outpatient care.

Her closing point was return on investment. A faster TB regimen saves lives, and those lives return to the workforce, generate income and pay taxes. The question for government, she said, is whether the patient benefits and the money delivers value.

▼WHERE TO INVEST

Predictive, preventive, corrective

Following Dr. Kaur’s session on pricing and public-private models, Prof. Ananth offered a way to think about where to put the money. Healthcare AI, he said, works at three levels: predictive, preventive and corrective. As you move from predictive to corrective, you move from data-rich to data-scarce, and from low cost to high cost.

DATA RICH · LOW COSTDATA SCARCE · HIGH COST
LEVEL 1
Predictive
Validated data exists, so translation into impact can happen now. Genomics is one example he gave.
LEVEL 2
Preventive
The bridge. Early screening and risk stratification turn prediction into action before disease advances.
LEVEL 3
Corrective
Data is thin, so more research and ground-level validation are needed. Expensive, and the least ready.

His conclusion was an investment argument. Put more resources where returns arrive early, at the predictive stage, rather than waiting for the corrective one. That also means a healthier nation as the system moves forward.

▼POLICY AND DATA RIGHTS

An honest answer on a gap that remains

In the policy round, the moderator asked how patient data rights can be protected when sensitive health data is collected from rural communities who may not fully understand data-sharing agreements. Prof. Ananth gave a plain answer. India is still getting there. As far as he knows, there is no healthcare-specific data framework, and the DPDP (Digital Personal Data Protection) Act is what the country has.

Dr. Amritraj added that the Act’s rules are yet to be fully in force, that patient consent will be needed even when hospital data is used for research, and that the world is moving towards a trusted execution environment in which even an administrator cannot view the data.

On training, Prof. Singh said capacity building and trust building have to go together. The frontline in India is made up of ASHA workers, ANMs (auxiliary nurse midwives), community health officers and primary healthcare staff. He proposed structured, practical training in five areas: AI and digital health literacy, including its limits; hands-on use of AI tools in a regulated environment; data literacy and safe record keeping; ethics and responsible use; and AI-assisted clinical decision making, which means interpreting AI risk alerts, following referral protocols and not treating AI like a chatbot such as ChatGPT.

Dr. Kaur had to leave at noon to catch a flight, so the last policy question, on how AI could change the economics of Indian health, went unanswered and the planned fourth segment was dropped. The moderator asked each remaining panellist for a one-minute close.

▼THE CLOSING CALL

Industry 5.0, a fluid mind and a white paper

Prof. Ananth’s closing remarks widened the frame. Industry 4.0 was about the internet of things and other technical aspects, he said. Industry 5.0 is primarily human-centric, and that does not mean humans are left out. It means people stay in charge of decisions while machines carry the routine work.

Humans are the ultimate decision makers.
PROF. M. M. ANANTH, CLOSING REMARKS

He also pushed back on a word he hears often at panels, the fixed mindset. A mind should never set, he argued. It should stay fluid enough to re-adapt and re-learn, and keep progressing with technology rather than without it.

He warned that those who do not use their faculties of judgement now will miss the bus. Then he made a proposal. AcadNet has spent the past twelve months working on this theme and holds substantive data of its own. Why not write a quick white paper, specific to India, and publish it in three to four months?

OPEN INVITATION
An India-specific white paper on AI in healthcare, targeted for publication in three to four months.
AcadNet is looking for contributors who want to come on board. The moderator noted the recommendation for the panel’s proceedings and said the organisers would follow up.
▼OTHER CLOSING REMARKS

Three more final words

Prof. Singh
CLOSING REMARK

He called for a well-organised marriage between technologists and medical professionals. Technology people, he said, do not always understand the medical and legal sides, such as where wellness ends and medical grade begins. GIMS, he noted, has already started a collaborative approach in which the people who build the models sit with doctors and learn their language. When that marriage works, the technology can reach the last mile.

Dr. Amritraj
CLOSING REMARK

AI will enter every aspect of life, he said, and the only job is to carry a regulated umbrella. Healthcare must make sure that umbrella is safe and validated, and also help Indian AI startups grow by giving them the right clinical problem, validating their solutions and promising to adopt them once validated. Otherwise Western startups will take over, as they have with medical devices. Uttar Pradesh has a policy allowing direct purchase up to Rs 50 lakh. Regulators, he said, should not only say what is wrong but show the right way and the processes that can help.

Prof. Adarsh Kumar
MODERATOR’S CLOSE

AI is not here to replace clinical judgment, he said, any more than a calculator replaced a mathematician. It is a high-speed pattern-matching assistant that handles repetitive cognitive load, catches what tired human eyes miss and gives clinicians more time to look at patients instead of screens. In the end, he said, the human eye and the human touch remain essential.

▼AUDIENCE QUESTIONS

What participants asked, and how Prof. Ananth answered

FROM THE CHAT BOX
Can AI become the great equaliser, giving a remote village the same medical intelligence as a premium urban hospital?
Prof. Ananth called it a very optimistic question and answered yes, if knowledge can be democratised in that fashion.
FROM THE CHAT BOX
What can AI do in veterinary and animal sciences?
It comes back to data, he said, and to the sanctity of that data. Prof. Singh agreed it is possible, with steps to follow: trustworthy data, collected in a regulated setting, then prototyping. Panellists noted that startups are already building pet diagnostics, and the order of priority is humans first, then animals.
FROM THE CHAT BOX
If an AI-assisted tool harms a patient, who is liable?
The panel’s answer was consistent: the clinician who uses the tool remains accountable. Prof. Ananth repeated that human in the loop is crucial, adding that it must apply once a tool is regulated. The moderator pointed to the legal idea of therapeutic misadventure, which can protect a doctor who used technology prudently and within validated limits.
FROM THE CHAT BOX
What are the scopes for collaboration?
Immense, said Prof. Ananth, from patient entry to patient exit. He recommended an academic setting as the best home for such work, with clinicians inside the team to validate the process and the outcomes.
FROM THE CHAT BOX
What stops marginalised communities from benefiting, and how can that change?
He offered three words: awareness, immersion and implementation. The so-called marginalised have smartphones, he said. An AcadNet check of more than 12,500 data points showed a surprising share of activity from the rural sector. Awareness that this technology can serve health is what is missing.
FROM THE CHAT BOX
Should we focus on mass screening for asymptomatic people, better data management and decision support for doctors?
Prof. Ananth agreed. In India, he said, there is a gap between knowing and implementation, and it has to be bridged at scale.
▼KEY TAKEAWAYS

Ten ideas to carry out of the room

01
Adoption is real, evidence is thin
Global AI-health papers rose from 28,180 to 49,394 in a year, but only 2.4 per cent of devices with clinical studies relied on randomised trial data.
02
Generative AI can assert confident nonsense
Creative ability brings hallucination. Final accountability and decisions stay with a person.
03
Human in the loop must not be a loophole
It is a safeguard for regulated tools, not an escape from regulation or from clinical validation.
04
Practise the four Cs
Cooperation, collaboration, co-creation and co-evolution across clinicians, technologists, AI specialists and policymakers.
05
Invest where data is rich
Predictive use is low cost and data rich. Corrective use needs more research and more money, so sequence the spend.
06
Validation is a process, not an opinion
Dr. Amritraj: protocol, research committee, ethics committee and a test licence come before any claim of validation.
07
Screening assists, treatment counts
Prof. Singh and Dr. Kaur: AI screens, it does not diagnose, and success is measured in people treated and value returned.
08
Train the frontline, pay for results
Five-part training for ASHA workers and health staff, then flat yearly pricing, pooled purchase and payment for treated cases.
09
Close the knowing-doing gap
Awareness, immersion, implementation. Rural India has smartphones. What it lacks is awareness of what the technology can do.
10
Write the India paper
AcadNet will convene contributors for an India-specific white paper in three to four months.
▼THE ACADNET LENS

Why human in the loop is an IACT question

This section is AcadNews Editorial’s own reading and not a panel statement. The panel’s strongest message was that tools, however good, are the easier half. Knowledge and technical skills can be updated or even automated. How a clinician, a founder or a policymaker uses them depends on who that person is.

That is the logic behind IACT (Interpersonal, Adaptability, Cognitive and Technical intelligence clusters), the framework Prof. Ananth’s AcadNet has built. In its research-validated finding, about 75 per cent of professional effectiveness comes from durable Interpersonal, Adaptability and Cognitive traits, and about 25 per cent from perishable Technical skills. An AI perspective sharpens the point. Models will keep absorbing the technical layer. The judgement to question a confident answer, the adaptability to re-learn, and the trust between a health worker and a patient remain human work, and IACT is built to measure them.

▼WHAT NEXT

From a Sunday panel to a working paper

Dr. Kailash Petkar, Secretary of ACSF India, closed the session by thanking participants and the Commonwealth Scholarship Commission UK for its financial support. He described point-of-care diagnostic tools reaching communities in the Sundarbans, with trained field workers screening door to door, as proof that validated tools plus capacity building can work. ACSF said its next activity is its annual day in December, planned in physical mode in Delhi.

ABOUT PROF. M. M. ANANTH
Founder of AcadNet (Academic Network), a DPIIT-recognised educational think tank at the intersection of academia, industry and policy. Holds a Cambridge PhD in Materials Science and is a DAAD and Commonwealth Fellow. Has served twice as Vice Chancellor, including as Founding Vice Chancellor of Adani University, and holds an advisory role with the Office of the Principal Scientific Adviser. Author of the IACT white paper Fostering Future Leaders and Global Professionals.
Source: ACSF India panel discussion, 15 November 2026, held on Zoom, with the official event flyer. Statistics are as cited by Prof. Ananth, checked against the AcadNet AI in Healthcare Evidence Brief.
AcadNews Editorial · AN

Leave a Reply

Your email address will not be published. Required fields are marked *